SAN DIEGO, Feb. 3, 2021 /PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced that the first type 1 diabetes (T1D) patients have been implanted in a Phase 2 clinical study utilizing encapsulated delivery of cells. The encapsulation system was developed in collaboration with W. L. Gore & Associates, Inc. ("Gore"), a global materials […]
